Insensitivity of chronic myeloid leukemia (CML) hematopoietic stem cells to tyrosine kinase inhibitors (TKIs) prevents eradication of the disease and may be involved in clinical resistance. For improved treatment results more knowledge about CML stem cells is needed. We here present a new flow cytometric approach enabling prospective discrimination of CML stem cells from their normal counterparts within single-patient samples. In 24 of 40 newly diagnosed CML patients residual normal CD34 þ CD38 À stem cells could be identified by lower CD34 and CD45 expression, lower forward/sideward light scatter and by differences of lineage marker expression (CD7, CD11b and CD56) and of CD90. fluorescent in situ hybridization (FISH) analysis on Fluorescence-activated cell sorting sorted cells proved that populations were BCR --ABL positive or negative and long-term liquid culture assays with subsequent colony forming unit assays and FISH analysis proved their stem cell character. Patients with residual non-leukemic stem cells had lower clinical risk scores (Sokal, Euro), lower hematological toxicity of imatinib (IM) and better molecular responses to IM than patients without. This new approach will expand our possibilities to separate CML and normal stem cells, present in a single bone marrow or peripheral blood sample, thereby offering opportunities to better identify new CML stem-cell-specific targets. Moreover, it may guide optimal clinical CML management.
INTRODUCTION
Major breakthroughs in chronic myeloid leukemia (CML) research have led to a revolution in therapy by the introduction of a relatively specific inhibitor of BCR --ABL activity, imatinib (IM) and, more recently, of even more potent tyrosine kinase inhibitors (TKIs) like nilotinib and dasatinib. In chronic phase, IM induces complete hematological responses in virtually all patients, whereas complete cytogenetic responses are achieved in almost 90% and progression free survival in 84% of patients. 1 --3 Response rates may even be higher with nilotinib and dasatinib. 4, 5 In a large clinical trial, patients who attained a BCR--ABL transcript level that was more than 1000-fold lower than at diagnosis (major molecular response, MMolR) had durable responses without any sign of progression. 1 Unfortunately, not all patients attain such a favorable response. Primary or secondary resistance, defined at the hematological level, may develop in B4% of chronic phase cases, whereas cytogenetic resistance may be observed in up to 10 --15% of patients. 1, 6 Besides, a small number of patients presents in advanced phases of the disease, where the efficacy of TKIs is limited. Most important, TKIs do not eradicate the disease, because leukemic stem cells appear to be inherently resistant against these compounds. This probably relates to several characteristics of the most primitive CML cells, like upregulation of BCR --ABL mRNA-and protein expression, 7 --9 reduced influx of IM into the cells due to low Oct-1 activity 10, 11 and increased activity of IM efflux pumps, like ABCB1 (also known as P-glycoprotein) and ABCG2 (also called BCRP). 9, 12 This may explain low sensitivity of primitive stem cells to both IM as well as second generation TKIs and to conventional chemotherapeutic drugs.
For development of more effective strategies that are able to eliminate these CML stem cells, better insight in their functional properties is needed. In vitro long-term culture experiments and fluorescent in situ hybridization (FISH) analysis or RT-PCR have revealed that BCR --ABL positive and negative stem cells co-exist in the CD34
þ CD38 À stem cell compartment in CML. However, up to now, only limited information has become available on how to study these separately in a direct way in freshly obtained diagnosis samples.
Recently, we demonstrated that malignant and benign stem cells in AML can be distinguished in a single bone marrow (BM) or peripheral blood (PB) sample by using flow cytometry. 13, 14 With a similar approach, we now show for the first time that also in CML, in a large proportion of patients, malignant and benign stem cells can be distinguished on the basis of light scatter properties, CD34 and CD45 expression and hematopoietic lineage marker expression. We also demonstrate that detection of residual normal hematopoietic stem cells at diagnosis, as determined by this flow cytometric approach, relates to an optimal subsequent response to IM.
with lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.4) for 10 min at 4 1C, or by direct lysis only in 13 cases. Both isolation procedures were evenly distributed among the cases with either one of the two flow cytometry patterns as further described. For control experiments, BM samples from eight healthy volunteers were used.
CD34 þ cell selection In order to increase speed of the Fluorescence-activated cell sorting (FACS) -procedure and depending on the percentage of CD34 þ cells in the samples, CD34 þ cells were isolated using CD34 Reagent and the AutoMacs automated selection device (both from Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Purity as assessed by flow cytometry was always more than 95%.
Flow cytometry Freshly isolated mononuclear cells or purified CD34
þ cells were incubated with monoclonal antibodies for 15 min at room temperature, washed once in PBS containing 0.1% HSA and analyzed by flow cytometry. Fluorescent-labeled antibodies were used as described in the Supplementary Appendix 1.
15 Data acquisition was performed using a 3-laser FACSCanto II flow cytometer (BD Biosciences, Erembodegem, Belgium). For data analysis FACSDiva software (BD Biosciences) was used.
FACS gating strategy and sorting By means of five-color FACS analysis, light scatter properties and expression of lineage marker (CD2, CD5, CD7, CD11b, CD19, CD22 and CD56), CD90 and CLL-1 were studied. Except for CD90, these markers are absent on normal CD34
þ CD38 À cells. 13 The gating strategy to identify CD34 þ CD38 À stem cells is shown in Figure 1 . On the basis of this, cells were sorted on a FACSAria cell sorter (BD Biosciences) into pure FCS and, after the sorting procedure, applied upon glass slides for FISH analysis, or used for further culture experiments. Cell doublets were excluded by plotting forward scatter (FSC)-area against FSC-width. In two cases, (no. 14 and 16), flow cytometry patterns of fresh and cryopreserved (RPMI/20% FCS/10% DMSO) samples could be compared and were found quite similar.
To estimate sorting purity, we FACS-sorted separate samples from five other CML patients (not used for experiments described in this paper), using a similar gating strategy, into FCS-coated test tubes. Next, purity of the sorted CD34
þ CD38 À subpopulations was tested by a second round of sorting. In these cases, average purity was 90% (range 80 --97).
Long-term suspension culture assays Long-term stroma-free suspension cultures were performed essentially as has been previously described. 16 The sorted (sub)populations were suspended in CellGro medium (Cellgenix, Vancouver, Canada) containing 20 ng/ml IL-3, 100 ng/ml Flt-3 ligand and 100 ng/ml SCF (all from Pepro Tech, Basel, Switzerland) before plating in 96 round-bottom-or 24-wells plates, depending on the number of available cells (Greiner, Frickenhausen, Germany). Suspension cultures were incubated at 37 1C in 5% CO 2 and received weekly half-medium and -cell changes (demipopulation). If sufficient cells (420 000) were available, colony forming unit-assays were performed every week as described previously. 15 Colonies of different sizes were plucked using very thin handmade glass pipettes or a standard laboratory pipette (Rainin, Mettler-Toledo, Tiel, The Netherlands) with 10 ml pipette tips and spread onto glass slides for FISH analysis (see below). This weekly procedure was continued for up to eight weeks or until no colony forming unit output was present anymore. In cases where the number of cells was very low, we harvested all cells at one time point only, that is, 5 weeks, without weekly demipopulations. In case, 16 cryopreserved cells were used for culture experiments. All other samples were freshly processed.
Fluorescent in situ hybridization FISH analysis on slides with sorted cells or colonies was performed using the Vysis LSI BCR/ABL ES Dual Color Translocation Probe (Abbott BV, Hoofddorp, The Netherlands) as described previously, with minor adaptations. 17 See Supplementary Appendix 2 for a detailed description of the procedure.
Colonies had to consist of at least 10 cells and were scored BCR --ABL positive or negative if at least 90% of all cells from that colony were either BCR --ABL positive or Ànegative. To prevent bias, scoring was performed in a blinded fashion.
Statistical analysis
Lineage marker expression is shown as a mean fluorescence intensity (MFI) ratio, calculated by the MFI of the population of interest, as generated by the FACS Diva software using FCS 2.0 files, divided by the MFI of the appropriate isotype controls. MFI ratio's were compared using Student's t-test (SPSS 17.0 software package, SPSS, Chicago, IL, USA). If necessary to obtain a normal distribution, data were log-transformed before t-testing. In case data remained non-normally distributed, Mann --Whitney U-tests were used. Sokal and Euro-scores were calculated according to Hehlmann et al. 18 and also compared using Student's t-test or Mann --Whitney U-test.
Cytogenetic responses were based on analysis of at least 20 metaphases. If cytogenetic analysis was unavailable, a BCR --ABL transcript level as measured by quantitative PCR of p1% on the international scale was considered equal to complete cytogenetic response. 19 An MMolR was defined as a BCR --ABL transcript level of p0.1% and a complete molecular response (CMolR) as a BCR --ABL level of p0.0032% according to the international scale. Differences between response rates and incidence of hematological toxicities were compared using the Fisher's exact test. P-values o0.05 were considered to indicate a statistically significant difference.
RESULTS

Flow Cytometry shows distinct subpopulations within the CML CD34
þ 38 À compartment Pattern 1. We set out to investigate whether the previously demonstrated marker and light scatter differences between leukemic and normal stem cells in AML could also be applied to CML. 13, 14 To this end, we examined fresh BM and/or PB samples of 40 newly diagnosed, untreated CML patients by flow cytometry.
Patient characteristics are shown in Table 1 . Using the gating strategy as shown in Figures 1a --h, two characteristic flow cytometrically determined patterns could be distinguished.
These patterns were very similar between PB and BM samples, as could be tested in 23 patients where both BM and PB samples were available. As we will show, these patterns allow for discrimination of leukemic and normal long-term clonogenic CD34 þ /38 À cells in a large proportion of patients. Figures 1g --i gives an example of the first pattern (patient number 1 in Table 1 ). In this sample, back gating of CD34 þ /38 À cells into a CD34/45 plot revealed two populations, one with high expression of both CD34 and CD45, while a second, separate population had lower CD34 and CD45 expression. Back gating both populations into a FSC/sideward scatter (SSC) plot showed that almost all cells with high CD34 and CD45 expression also had high FSC and (somewhat) higher SSC. Next, these populations were tested for expression of a set of markers that is used in AML for leukemic stem cell identification, that is, CD2, CD5, CD7, CD11b, CD19, CD22, CD56, CLL-1 and CD90. 13, 15 CD2, CD5, CD19, CD22 and CLL-1 were all negative on the different populations. However, we could demonstrate that in all tested cases, the CD34/45 high population had (variable) expression of CD7, CD11b, CD56 and CD90 (see Supplementary  Figures 1A --D, purple bars) . In contrast, expression of these markers on the CD34/45 low cells depended on their light scatter properties: CD34/45 low cells with high FSC/SSC had expression levels of CD7,CD11b, CD56 and CD90 that were not significantly different from those of the CD34/45 high cells (compare green bars with purple bars in Supplementary Figures 1A --D Figures 1A--D) . Compared with the CD34/45 high population of the first described patient group, CD90 was significantly higher expressed in the pattern 2 patient group, whereas CD11b was significantly lower (Supplementary Figures 1A --D 
and CD34/CD45
high /CD90 high cells showed that the subpopulations sorted on these characteristics have long-term clonogenic ability (see Supplementary Figure 2) . Results of FISH analysis on plucked colonies are shown in Table 3 and confirm for almost all samples that the colonies from the cultured sorted subpopulations represent either leukemic or normal long-term clonogenic cells. As shown, in patient 16, 39% BCR --ABL positive colonies were detected in the CD34/45 low population. This corresponds with 38% of cells in the CD34/45 low population being FSC/SSC high using flow cytometry (See legends of Table 2 ) and FISH results (see Table 2 ) at diagnosis. Detailed FISH data on long-term culturederived colonies are shown in Supplementary Table 1 . Summarizing, leukemic long-term clonogenic CD34 þ CD38 À cells can in all patients be found in the CD34/45 high population, which also has high light scatter properties and often shows aberrant lineage marker and CD90 expression. In contrast, normal long-term clonogenic CD34 þ CD38 À cells can be found in a subset of patient samples, have both low CD34/45 expression and low light scatter properties and never express lineage markers. Besides, they have low expression of CD90. At last, there is a population of CD34/45 low cells with high light scatter properties, variable lineage marker-and dim CD90 expression, which likely is Ph þ .
Correlations with clinical risk scores, IM toxicity and molecular responses We investigated whether the presence or absence of residual normal stem cells had implication for prognosis, treatment response and toxicity. Compared with patients with only malignant stem cells present (patients 25 --40), patients with detectable residual normal stem cells (patient 1 --24) had significantly lower Sokal-(1.00 versus 1.56; P ¼ 0.001) and Euroscores (925 versus 1345; P ¼ 0.003; for individual values, see Table 1 ).
For assessment of hematological toxicity of IM, patients receiving combination therapy with cytarabine and IM (which was given as part of the HOVON-51 study 21 ) were excluded. Thus, only patients taking IM 400 mg as monotherapy for at least 6 months were analyzed. Of the patients with residual normal stem cells, only one of 16 evaluable patients (6%) developed grade 3 neutropenia after the start of IM. In contrast, in a significantly (P ¼ 0.018) higher percentage of patients (5 out of ten) without detectable normal stem cells, grade 3 or 4 neutropenia and/or thrombocytopenia was seen.
Likewise, response was evaluated only in patients taking IM 400 mg o.d. for at least 1 year. All 15 (100%) evaluable patients who had detectable residual normal stem cells by flow cytometry (pattern 1) had achieved a complete cytogenetic response by 1 year and a MMolR by 1.5 years, which, according to European Leukemia Net criteria, constitutes an optimal response. 22 In the nine evaluable pattern two patients without detectable residual normal stem cells, six patients (67%) attained complete cytogenetic response at 1 year of treatment and these six also reached MMolR at 1.5 years. According to ELN criteria, the other three patients were treatment failures at both time points. 22 One of these patients developed a T315I mutation, whereas in the other two no ABL mutations could be detected using standard automated sequence analysis. CMolR (CMolR; 44.5 log reduction in BCR --ABL level) was achieved in 12 of 15 patients (80%, mean follow-up 1026 days, range 642 --1449) in the first group, compared with only two of nine (22%) in the latter group (mean 834 days, range 453 --1398, difference in follow-up duration nonsignificant). Differences in these MMolR and CMolR rates were statistically significant (P ¼ 0.042 and P ¼ 0.01, respectively).
DISCUSSION
Previously, identification of malignant versus residual benign stem cells in CML was done in an indirect way by performing FISH analysis or RT-PCR on colonies that had grown out of remaining viable cells after at least 5 weeks of culture. 20, 23 Next to that indirect technique, it was shown that lack of HLA-DR expression on CD34 þ /lineage marker À cells identified a population of cells in the BM, that was mostly Philadelphia negative and had long-term clonogenic capacity, whereas CD34 þ HLA-DR þ cells were for the largest part malignant. 24, 25 However, additional studies showed less clear separation between leukemic and normal cells by HLA-DR-based sorting. 26 In this report, we demonstrate that, within single BM or PB samples of a majority of CML patients, additional characteristics, as defined by advanced multiparameter flow cytometry, enable improved, prospective discrimination between CML longterm clonogenic cells ('candidate stem cells') and their normal counterparts. Moreover, our data suggest that the presence of residual normal stem cells in diagnostic CML samples, as detected by flow cytometry, may have important prognostic significance as patients that had no detectable residual Ph À stem cells attained poorer response to and had more hematological toxicity on IM.
Normal long-term colony-forming cells within CML BM or blood were CD34/45 low , had low light scatter properties, lacked lineage marker expression and were CD90 dim . Remarkably, both their light scatter as well as their CD90 expression were lower than that of normal CD34
þ 38 À cells in normal BMs. In contrast, leukemic longterm colony forming cells were CD34/45 high , had higher forward and sideward scatter, variable lineage marker and higher CD90 expression.
To our knowledge, this high CD90 expression in CML stem cells has not been reported previously, although some studies have assessed CD90 expression levels in several subsets of CML BM or PB samples. Thy-1 or CD90 expression marks a subset of CD34 þ cells that is capable of full hematopoietic reconstitution after stem cell transplantation. 27 --29 In AML, CD90 expression is correlated with factors that represent adverse clinical risk factors, like secondary AML, higher age and poor risk cytogenetics. 30 The marked difference in CD90 expression between normal stem cells in CML marrow or blood and leukemic stem cells is for a substantial part due to the (relative to normal BM) low CD90 expression in the normal stem cells. The reason for this is unknown, but it illustrates that normal stem cells in a leukemic microenvironment behave differently from normal stem cells in normal BM: 31 apart from CD90 expression, compared with normal stem cells in CML BM, FSC/SSC was higher in stem cells from normal BM (this paper), a phenomenon also observed in AML BM for FSC/SSC and CD34 expression (Terwijn and Schuurhuis, submitted).
The data presented here are clinically relevant. First, the ability to reliably discriminate malignant from benign stem cells within single patients will make molecular and functional characterization of the CML stem cell compartment, for example, by gene expression array studies, much more informative. This is especially of interest in cases where the number of residual normal stem cells is quite substantial: in our pattern 1 patients this may be as high as 61% of the total stem cell compartment. Thus, background 'noise' because of mixing of leukemic and non-leukemic stem cells as well as to interindividual differences in non-relevant gene expression can now be reduced by accurate FACS sorting of separate populations. This may improve development of treatments with an optimal therapeutic window as now the absence of putative targets in or on the simultaneously present normal stem cells can be taken into account.
Second, quantitation of the malignant and benign stem cells in CML may have clinical value in addition to the already used prognostic indices like the Sokal-and Euro-scores.
In clinical trials, lower Sokal-or Euro-risk scores were associated with higher response rates to both conventional treatment and to tyrosine kinase inhibition. 1, 18 Remarkably, in our study the presence of detectable residual normal stem cells correlated with lower Sokal-and Euro-scores and predicted for a 100% MMolR rate, whereas resistance to IM was seen in 33% of patients where no residual normal stem cells could be detected. Moreover, grade 3/4 hematological toxicity was much more frequent in the group of patients without residual normal stem cells.
Residual leukemic stem cell enumeration may also serve as a relevant surrogate end point in clinical studies with new (stem cell targeting) drugs. Furthermore, clinical CML management might in future be guided by detection of normal and residual leukemic stem cells in patients under TKI-treatment. As almost 40% of IM-treated patients with long-lasting CMolRs maintained their response after stopping IM, 32 it would be highly relevant to see whether persistent remission could be predicted by flow cytometric analysis of the primitive stem cell compartment. With that in mind, a Dutch --Belgian HOVON study has been initiated in patients with long-lasting CMolRs. After interruption of IM, regular evaluation of the CD34 þ CD38 À stem cell compartment using our flow cytometric strategy, together with quantitative PCR on BCR --ABL, will be performed to guide re-initiation of IM in these patients. We have also just started clinical studies in second generation TKI-treated patients, to assess the predictive role of this flow cytometric approach.
The third relevant issue is that, although CD56 expression was reported on short-term clonogenic CD34
þ CML cells in a small fraction of CML patients, 33 in most studies, CML stem cells are defined by their lineage negativity. 8, 34, 35 We now show that lineage marker expression is also a property of FSC/SSC high BCR --ABL positive cells that had clonogenic capacity in long-term liquid culture, thereby resembling the AML stem cell compartment. 13 Possibly, these cells differ in more characteristics (in gene or protein expression, biological behavior) from their marker positive counterparts. Using only marker negative leukemic cells for in vitro or in vivo experiments would thereby potentially bias results.
In conclusion, flow cytometric discrimination of leukemic and normal candidate stem cells is an exclusive tool for defining new therapeutic targets and applied diagnostics in CML. We are now exploring this technique for the analysis of differentially expressed genes in malignant vs benign stem cells, and are planning in-vivo experiments with leukemic stem cells that have been identified by flow cytometry.
